Comparison of Two Analgosedation Regimens in Transfemoral TAVI: Propofol-Dexmedetomidine vs. Propofol-Remifentanil
The Heart Surgery Forum · 2026-04-02 · 29 (4)
DOI: 10.31083/hsf47124 ↗At a glance
Journal article in The Heart Surgery Forum, published online on 2026-04-02. Written by Erik Thies Merks and 5 co-authors. 33 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
This study aimed to compare the hemodynamic effects of two analgosedation regimens, Remifentanil/Propofol vs. Dexmedetomidine/Propofol, during transfemoral transcatheter aortic valve implantation (tf-TAVI).
Methods
In this monocentric, prospective, non-randomized observational study, 143 patients undergoing tf-TAVI between November 2021 and November 2023 were analyzed. Patients received either Remifentanil/Propofol or Dexmedetomidine/Propofol as part of their standard sedation regimen. A sensitivity analysis using propensity score matching was performed to support the primary analysis.
Results
The primary outcome was circulatory stability, assessed by the need for catecholamines to maintain a mean arterial pressure (MAP) of 65 mmHg. Catecholamine use was significantly higher in the Dexmedetomidine group (78% vs. 55%; p = 0.012). No significant differences were observed in major post-procedural complications (Remifentanil: 19.05% vs. Dexmedetomidine: 13.56%; p = 0.389) or postoperative delirium scores. However, intraoperative agitation, defined as observed procedure disruption, was significantly less frequent in the Remifentanil group (33% vs. 69%; p = 0.01). Propensity score matching confirmed the robustness of these findings.
Conclusion
In conclusion, both sedation strategies were associated with comparable overall clinical outcomes in patients undergoing tf-TAVI. However, our findings suggest that a tailored sedation approach may be warranted: Remifentanil–Propofol may be preferable in patients with fragile hemodynamics, whereas dexmedetomidine–propofol may represent a safer option in patients at risk for respiratory compromise. These observations support an individualized, patient-centered sedation strategy rather than a one-size-fits-all approach.
Cite
APA
Merks, E. T., Heide, M. V. D., Meyer-Jark, T., Wille, C., Popov, A., & Kerner, T. (2026). Comparison of Two Analgosedation Regimens in Transfemoral TAVI: Propofol-Dexmedetomidine vs. Propofol-Remifentanil. The Heart Surgery Forum, 29(4). https://doi.org/10.31083/hsf47124
Vancouver
Merks ET, Heide MVD, Meyer-Jark T, Wille C, Popov A, Kerner T. Comparison of Two Analgosedation Regimens in Transfemoral TAVI: Propofol-Dexmedetomidine vs. Propofol-Remifentanil. The Heart Surgery Forum. 2026;29(4). doi:10.31083/hsf47124
BibTeX
@article{Merks2026,
author = {Merks, Erik Thies and Heide, Michael von der and Meyer-Jark, Ties and Wille, Carolin and Popov, Aron-Frederik and Kerner, Thoralf},
title = {Comparison of Two Analgosedation Regimens in Transfemoral TAVI: Propofol-Dexmedetomidine vs. Propofol-Remifentanil},
journal = {The Heart Surgery Forum},
year = {2026},
volume = {29},
number = {4},
doi = {10.31083/hsf47124}
}
EUVIMED